Host insulin resistance caused by Porphyromonas gingivalis -review of recent progresses

is a Gram-negative oral anaerobic bacterium that plays a key role in the pathogenesis of periodontitis. expresses a variety of virulence factors that disrupt innate and adaptive immunity, allowing to survive and multiply in the host and destroy periodontal tissue. In addition to periodontal disease,...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in cellular and infection microbiology 2023-07, Vol.13, p.1209381
Main Authors: Jia, Shuxian, Li, Xiaobing, Du, Qin
Format: Article
Language:English
Subjects:
Alzheimer’s disease
Base Composition
Cellular and Infection Microbiology
diabetes
FFA
Humans
Insulin
Insulin Resistance
Phylogeny
Porphyromonas gingivalis
RNA, Ribosomal, 16S
Sequence Analysis, DNA
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:is a Gram-negative oral anaerobic bacterium that plays a key role in the pathogenesis of periodontitis. expresses a variety of virulence factors that disrupt innate and adaptive immunity, allowing to survive and multiply in the host and destroy periodontal tissue. In addition to periodontal disease, is also associated with systemic diseases, of which insulin resistance is an important pathological basis. causes a systemic inflammatory response, disrupts insulin signaling pathways, induces pancreatic β-cell hypofunction and reduced numbers, and causes decreased insulin sensitivity leading to insulin resistance (IR). In this paper, we systematically review the studies on the mechanism of insulin resistance induced by , discuss the association between and systemic diseases based on insulin resistance, and finally propose relevant therapeutic approaches. Overall, through a systematic review of the mechanisms related to systemic diseases caused by through insulin resistance, we hope to provide new insights for future basic research and clinical interventions for related systemic diseases.
ISSN:2235-2988
2235-2988
DOI:10.3389/fcimb.2023.1209381